Acute Myocardial Infarction, Adiposis; Heart, Myocardial Reperfusion Injury, Obesity
Conditions
Keywords
Adiposis, Obesity, Acute Myocardial Infarction, Percutaneous Coronary Intervention, Left Ventricular Function
Brief summary
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With acute myocardial infarction (AMI) Who Have Undergone Percutaneous Coronary Intervention (PCI).
Detailed description
Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are involved in maintaining varieties of processes such as, appetite and satiety, energy expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin secretion in pancreatic β-cells. Adipokines may contribute to reduce scar formation and improve cardiac function in acute myocardial infarction (AMI). Reperfusion therapy such as percutaneous coronary intervention (PCI) should be administered to all eligible patients with AMI symptom onset within the prior 12 hours. However, our previous work showed that obese patients may benefit more from PCI. Thus, the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with acute myocardial infarction (AMI) who have undergone PCI.
Interventions
PROCEDUREPCI
percutaneous coronary intervention (PCI)
Sponsors
Xijing Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
age between 20 and 70 years old STEMI and NSTMI according to the WHO definition PCI \<12 hours from the onset of symptoms
Exclusion criteria
previous myocardial infarction (MI) cardiomyopathy atrial fibrillation or flutter previous heart surgery severe valvular heart disease disease of the hematopoietic system NYHA functional class IV heart failure at baseline severe renal, lung and liver disease cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patient death during the follow up period | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Myocardial perfusion scores as evaluated by Single-photon emission computed tomography (SPECT) | 1 year |
| Infarct size as evaluated by Single-photon emission computed tomography (SPECT) | 1 year |
| Number of target vessel revascularization | 1 year |
| Left ventricular ejection fraction | 1 year |
| Scores on the Seattle angina questionnaire | 1 year |
| six-min walk distance (6MWD) | 1 year |
| Angina class according to the canadian cardiovascular society (CCS) classification | 1 year |
Countries
China
Outcome results
None listed